1. Home
  2. WST vs RPRX Comparison

WST vs RPRX Comparison

Compare WST & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Pharmaceutical Services Inc.

WST

West Pharmaceutical Services Inc.

HOLD

Current Price

$271.13

Market Cap

20.2B

Sector

Health Care

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$38.43

Market Cap

16.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WST
RPRX
Founded
1923
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.2B
16.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WST
RPRX
Price
$271.13
$38.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
4
Target Price
$346.78
$45.75
AVG Volume (30 Days)
661.3K
4.0M
Earning Date
10-23-2025
11-05-2025
Dividend Yield
0.33%
2.29%
EPS Growth
0.17
N/A
EPS
6.75
1.75
Revenue
$3,017,900,000.00
$2,349,844,000.00
Revenue This Year
$7.01
$37.13
Revenue Next Year
$6.20
$1.48
P/E Ratio
$39.63
$21.92
Revenue Growth
4.92
3.70
52 Week Low
$187.43
$24.05
52 Week High
$348.90
$41.24

Technical Indicators

Market Signals
Indicator
WST
RPRX
Relative Strength Index (RSI) 48.36 46.88
Support Level $265.39 $37.88
Resistance Level $274.56 $38.93
Average True Range (ATR) 7.07 0.77
MACD -0.69 -0.21
Stochastic Oscillator 31.39 20.00

Price Performance

Historical Comparison
WST
RPRX

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: